Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion ...

Recursion Pharmaceuticals (RXRX) ended the recent trading session at $3.53, demonstrating a +2.02% change from the preceding day's closing price. This move outpaced the S&P 500's daily gain of 0.56%.

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is ...

NVIDIA’s most recent 13F filing showed no position in Recursion Pharmaceuticals, indicating a complete exit from its previous ...

In the biotech sphere, ARK continued its accumulation of CRISPR Therapeutics AG (NASDAQ:CRSP) by acquiring 37,075 shares worth $1.97 million. This purchase is part of a broader strategy, as ARK has ...

If you are trying to figure out whether Recursion Pharmaceuticals is attractively priced or a high risk speculation, a useful ...

Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, 2026, the Compensation Committee of Recursion's Board of ...

This week, I had to make one of the most difficult decisions of my career: saying goodbye to 20% of the team at Recursion. The process was extraordinarily painful, and the costs were heartbreakingly ...

Recursion Pharmaceuticals, a drug discovery company that applies artificial intelligence to biology, is shoring up its technology platform by buying two startups that bolster its chemistry ...